Groundbreaking Coverage of AdMeTech in the Wall Street Journal

You are here:

Home
Groundbreaking Coverage of AdMeTech in…

Groundbreaking, three-part coverage of AdMeTech’s research program in prostate MRI and its potential impact on screening, diagnosis and treatment by the Wall Street Journal. April 2009

Part One

The Man, the Gland, the Dilemmas

You’ve been getting annual blood tests to check for prostate cancer. But two big studies in the New England Journal of Medicine just found that screening for PSA — prostate specific antigen — doesn’t save many lives. Should you keep checking it?

Your biopsy was negative for prostate cancer but your PSA keeps rising. Should you stop worrying — or have another biopsy? (Read More)

Part Two

Prostate Cancer: Weighing Options

You’ve been diagnosed with prostate cancer and after the shock comes confusion.

Should you treat it fast with surgery but face an immediate risk of sexual and urinary problems? Or should you opt for weeks of daily radiation treatments and side effects that set in more slowly? Should you also use hormone therapy that may shrink the cancer — and your sex drive along with it? Or should you just monitor your cancer and hope you’ll catch it if it starts to spread out of control? (Read More)

Part Three

Health Matters

Weighing the Benefits of ‘Watchful Waiting’ for Prostate Cancer

One evening a week for more than 10 years, a group of 15 to 25 men have met in a conference room in New York to talk about their prostate cancer. In the beginning, most of them swapped stories about their surgery or radiation, says Darryl Mitteldorf, a social worker who runs the group. Now, he says, more than half are doing “watchful waiting” — just monitoring their cancer to see if it grows. (Read More)